FDA EIR - Sherman's 1400 Broadway, N.Y.C. Ltd. - February 11, 2015

Sherman's 1400 Broadway, N.Y.C. Ltd., a tobacco manufacturing firm in Greensboro, NC, underwent a comprehensive surveillance inspection by the FDA from February 10-11, 2015. Conducted under the regulatory framework of the FD&C Act, as amended by the Family Smoking Prevention and Tobacco Control Act, the inspection covered receiving, manufacturing, packaging, labeling, and distribution operations.

Crucially, the FDA found no objectionable conditions during this inspection, and therefore, an FDA 483, Inspectional Observations, was not issued. This indicates that no significant compliance deficiencies requiring immediate formal action were identified. While a previous inspection in 2013 had resulted in a Voluntary Action Indicated (VAI) classification regarding "100% Natural Tobacco" labeling, the current report did not cite this as an objectionable condition warranting a 483.

Management was warned of their ongoing responsibility for compliance with the FD&C Act and potential penalties for non-compliance. Discussions regarding operational improvements, such as formal training programs, raw material release procedures, and written complaint and recall processes, were offered as suggestions for consideration based on practices in other regulated industries, rather than specific required actions for tobacco products at that time.